ADMA Biologics Inc

Grossman’s fresh buy of 6,400 ADMA Biologics shares at $7.91 signals confidence amid a steep stock decline, hinting at a potential breakthrough and investor optimism.

ADMA Biologics insider moves: CFO’s RSU grant valued over $885K, CEO’s buy‑sell strategy, and COO’s sales—all impact short‑term volatility and long‑term commitment.

ADMA Biologics insider buying: COO Kaitlin Kestenberg‑Messina adds 91k shares, signaling management confidence amid market volatility and pipeline growth.